Jazz Pharmaceuticals enters mid-June with an unusual combination: short sellers are beating a sustained retreat while analysts are racing to lift their targets — and Bank of America fired the latest shot this morning.
The analyst momentum here is hard to ignore. BofA's Jason Gerberry raised his target from $281 to $307 this morning, maintaining a Buy rating — one of at least six upward revisions since the Q1 print on May 6. UBS went further, upgrading outright from Neutral to Buy and lifting its target to $307, a move that represents the most aggressive directional shift in the recent cluster. Piper Sandler jumped its target from $232 to $301, and Bernstein started coverage at Market Perform with a $229 target — roughly where the stock trades now. The mean target across the Street is $256, implying about 12% upside from the current $229.19 close. The consensus score ranks in the 99th percentile on analyst recommendation differential, meaning the bull tilt is unusually lopsided relative to peers.
The bull case rests on the Q1 earnings beat and pipeline progression, particularly Epidiolex and zanidatamab. Bears point to generic erosion in the oxybate franchise and competitive pressure in oncology — a headwind that is real but, in the view of most analysts currently, manageable. At 9x trailing earnings and 8.1x EV/EBITDA, the valuation is not demanding for a pharma name with this kind of momentum. The EV/EBITDA multiple has actually drifted slightly lower over the past month despite the stock being up 1.5%, which means the earnings base is expanding faster than the price.
Short sellers have been stepping back for weeks. Short interest dropped nearly 9% on the week to 7.2% of the free float — down from around 8.7% a month ago and at its lowest level in the 30-day window. The unwind has been consistent rather than violent: shares short fell from roughly 5.4 million in early May to 4.4 million by June 9. Borrow conditions remain loose, with availability running at 569% — meaning there are nearly six shares available to borrow for every one already lent out. Cost to borrow is running at 0.46%, which has nearly doubled over the past month in percentage terms but remains low in absolute terms and carries no real squeeze pressure. The lending market is not sending distress signals; shorts are simply choosing to reduce exposure.
Options positioning is neutral to slightly constructive. The put/call ratio is 0.76, just a fraction above its 20-day average of 0.75 and well inside one standard deviation — a z-score of 0.22. There is no hedging spike, no defensive surge. The 52-week high on the PCR was 1.54, so current levels are far from crowded on the downside. The stock gained 1.4% on the week and is up 1.5% over the past month, modestly lagging close peers: SUPN added 3.6% on the week and INDV surged 13.5%, while RAPP slipped 2.3%.
The institutional picture adds a layer of context. Founder and Chairman Bruce Cozadd sold 6,000 shares on June 1 at $235, his second such block sale in two months. The Chief Commercial Officer sold nearly $1.6 million worth in late May. Net insider selling over 90 days totals roughly $16 million — not a trivial number, and a contrast to the bullish analyst tone. These are likely scheduled disposals rather than conviction calls, but the directional read is worth tracking. BlackRock is the largest holder at 8.9% and added to its position through May. Fidelity more than doubled its stake, reporting a net addition of 1.47 million shares as of late May.
The next earnings date is August 5. The last two prints produced same-day moves of roughly 7% and 10% respectively — both to the upside. With shorts continuing to cover and the analyst community consolidating around a constructive view, what to watch is whether the oxybate franchise erosion data sharpens between now and August and whether any pipeline readouts on zanidatamab shift the bear case materially before then.
See the live data behind this article on ORTEX.
Open JAZZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
